QQ客服 官方微博 反馈留言

	A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B
	Xie, Qing; Zhou, Huijuan; Bai, Xuefan; Wu, Shuhuan; Chen, Jian-Jie; Sheng, Jifang; Xie, Yao; Chen, Chengwei; Chan, Henry Lik-Yuen; Zhao, Mianzhi
刊名	CLINICAL INFECTIOUS DISEASES
	2014
卷号	59期号:12
关键词	hepatitis B viral hepatitis liver clinical pharmacology
ISSN号	1058-4838
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3660286
专题	上海中医药大学
推荐引用方式 GB/T 7714	Xie, Qing,Zhou, Huijuan,Bai, Xuefan,et al. A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B[J]. CLINICAL INFECTIOUS DISEASES,2014,59(12).
APA	Xie, Qing.,Zhou, Huijuan.,Bai, Xuefan.,Wu, Shuhuan.,Chen, Jian-Jie.,...&Zhao, Mianzhi.(2014).A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B.CLINICAL INFECTIOUS DISEASES,59(12).
MLA	Xie, Qing,et al."A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B".CLINICAL INFECTIOUS DISEASES 59.12(2014).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。